Peptide Database

A GLP-1 receptor agonist used for type 2 diabetes and weight management. One of the most studied peptides for metabolic health.

A dual incretin agonist targeting both GIP and GLP-1 receptors. Shows superior weight loss and glycemic control compared to GLP-1-only agonists.

A modified fragment of human growth hormone (amino acids 177-191) that stimulates lipolysis without the growth-promoting or diabetogenic effects of full GH.

A triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Shows the highest weight loss of any obesity drug in trials.

A long-acting amylin analog being developed in combination with semaglutide (CagriSema) for obesity and type 2 diabetes treatment.